Praxis Precision Medicines logo

Praxis Precision Medicines

Biotechnology

Boston, Massachusetts, United States
200-500 employees
Founded 2015

Praxis Precision Medicines is a clinical-stage, central nervous system (CNS) precision neuroscience biopharmaceutical company that translates insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. It is publicly traded on Nasdaq under ticker PRAX and is transitioning toward commercialization of its first therapies.

  • Cerebrum™ small molecule platform (ulixacaltamide, vormatrigine, relutrigine, PRAX-020, PRAX-050)
  • Solidus™ antisense oligonucleotide platform (elsunersen, PRAX-080, PRAX-090, PRAX-100)

Open roles at Praxis Precision Medicines

33 matching roles

Showing 12 of 33 roles